CA240-0009: A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9) (clinicaltrials.gov) - Sep 19, 2026 - P2 | N=182 | Recruiting | Sponsor: Bristol-Myers Squibb | N=130 ➔ 182
Enrollment change • Monotherapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MTAP
|